TY - JOUR
T1 - Effect of a leukotriene receptor antagonist on the prevention of recurrent asthma attacks after an emergency room visit
AU - Matsunaga, Kazuto
AU - Nishimoto, Takeshi
AU - Hirano, Tsunahiko
AU - Nakanishi, Masanori
AU - Yamagata, Toshiyuki
AU - Minakata, Yoshiaki
AU - Kuroda, Mayu
AU - Ikeda, Takeshi
AU - Nakanishi, Hirotaka
AU - Ichinose, Masakazu
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2004/12
Y1 - 2004/12
N2 - Background: The efficacy of montelukast, a specific cysteinyl leukotriene receptor antagonist, in preventing recurrent asthma attacks was evaluated for post-emergency management of acute asthma exacerbation. Methods: Twenty-two patients with a history of chronic asthma whose symptoms were responsive to an inhaled β-adrenergic receptor agonist in an emergency room setting, were randomized into two groups, those with and those without montelukast (n = 11 for each group). Patients in the montelukast group received an oral dose of 10 mg montelukast before leaving the emergency room following rescue treatment with an inhaled β-adrenergic receptor agonist. Patients in both groups were instructed to use an inhaled β-adrenergic receptor agonist for shortness of breath or dyspnea in post-emergency management. Additional β-adrenergic receptor agonist use, subjective asthma symptoms, sleep impairment, additional emergency visits and/or hospitalization were monitored for 24 hours following the emergency room visit. Results: In the montelukast group, the need for a rescue β-adrenergic receptor agonist was significantly decreased; 54.5% of patients in the montelukast group required use of β-adrenergic receptor agonist compared with 100% in the non-montelukast group (P < 0.05). The average number of uses of a β-adrenergic receptor agonist was 2.67 ± 3.58 times/ 24 h in the montelukast group compared with 11.95 ± 3.60 times/24 h in the non-montelukast group (P < 0.01). The average subjective asthma symptom scores were significantly decreased in the montelukast group, whereas no score change occurred in the non-montelukast group. The sleep impairment score was significantly lower in the montelukast group compared with that in the non-montelukast group (P < 0.05). No patients in either group had an emergency visit or hospitalization during this period. Conclusions: The results demonstrate that montelukast can prevent recurrent asthma exacerbations in the home environment.
AB - Background: The efficacy of montelukast, a specific cysteinyl leukotriene receptor antagonist, in preventing recurrent asthma attacks was evaluated for post-emergency management of acute asthma exacerbation. Methods: Twenty-two patients with a history of chronic asthma whose symptoms were responsive to an inhaled β-adrenergic receptor agonist in an emergency room setting, were randomized into two groups, those with and those without montelukast (n = 11 for each group). Patients in the montelukast group received an oral dose of 10 mg montelukast before leaving the emergency room following rescue treatment with an inhaled β-adrenergic receptor agonist. Patients in both groups were instructed to use an inhaled β-adrenergic receptor agonist for shortness of breath or dyspnea in post-emergency management. Additional β-adrenergic receptor agonist use, subjective asthma symptoms, sleep impairment, additional emergency visits and/or hospitalization were monitored for 24 hours following the emergency room visit. Results: In the montelukast group, the need for a rescue β-adrenergic receptor agonist was significantly decreased; 54.5% of patients in the montelukast group required use of β-adrenergic receptor agonist compared with 100% in the non-montelukast group (P < 0.05). The average number of uses of a β-adrenergic receptor agonist was 2.67 ± 3.58 times/ 24 h in the montelukast group compared with 11.95 ± 3.60 times/24 h in the non-montelukast group (P < 0.01). The average subjective asthma symptom scores were significantly decreased in the montelukast group, whereas no score change occurred in the non-montelukast group. The sleep impairment score was significantly lower in the montelukast group compared with that in the non-montelukast group (P < 0.05). No patients in either group had an emergency visit or hospitalization during this period. Conclusions: The results demonstrate that montelukast can prevent recurrent asthma exacerbations in the home environment.
KW - Asthma exacerbation
KW - Leukotriene receptor antagonist
KW - Montelukast
KW - β-adrenergic receptor agonist
UR - http://www.scopus.com/inward/record.url?scp=19944417248&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19944417248&partnerID=8YFLogxK
U2 - 10.1111/j.1440-1592.2004.00359.x
DO - 10.1111/j.1440-1592.2004.00359.x
M3 - Article
AN - SCOPUS:19944417248
VL - 53
SP - 341
EP - 347
JO - Allergology International
JF - Allergology International
SN - 1323-8930
IS - 4
ER -